Roche Enters $2.3 Billion Collaboration with Nurix Therapeutics for Blood Cancer Drug
Roche has entered into a licensing and collaboration agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg, an investigational drug targeting blood cancers. The deal is valued at up to $2.3 billion, including upfront payments of $700 million and milestone-based incentives.
Tickers: $NRIX
Topics: Blood Cancer Research Drug Development Pharmaceuticals